AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27893884 — intervention group
Group type: EXPERIMENTAL
Intervention: GOC video decision aid plus structured discussion
Number of subjects: 302
Study 27893884 — intervention group
Group type: COMPARATOR
Intervention: Attention control with informational video and usual care planning
Number of subjects: 302
Study 25545238 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 25545238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 25545238 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan plus hydrochlorothiazide
Number of subjects: 0
Study 25545238 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan alone
Number of subjects: 0
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal cystoscopy at incontinence surgery
Number of subjects: 1830
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic urethropexy and retropubic midurethral sling (MUS) procedures
Number of subjects: 1830
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous pubovaginal sling procedures
Number of subjects: 1830
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator MUS
Number of subjects: 1830
Study 24380742 — intervention group
Group type: COMPARATOR
Intervention: Trocar perforation
Number of subjects: 1830
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, vaginal deliveries, and blood loss
Number of subjects: 1830
Study 24380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and smoking history
Number of subjects: 1830
Study 22958651 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 214
Study 22958651 — intervention group
Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (WLE)
Number of subjects: 214
Study 19183227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 485
Study 19183227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 485
Study 19183227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 17409390 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological Cost Index
Number of subjects: 27
Study 17409390 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen cost
Number of subjects: 27
Study 17409390 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 27
Study 17409390 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 27
Study 15048065 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 expression threshold >=7%
Number of subjects: 289
Study 15048065 — intervention group
Group type: COMPARATOR
Intervention: CD38 expression threshold >=30%
Number of subjects: 289
Study 15048065 — intervention group
Group type: COMPARATOR
Intervention: Intermediate values between 7% and 29% CD38 positive cells
Number of subjects: 289
Study 15048065 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 expression threshold <7%
Number of subjects: 289
Study 15048065 — intervention group
Group type: COMPARATOR
Intervention: CD38 expression threshold >=30% and >=7%
Number of subjects: 289
Study 11437863 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal insole support
Number of subjects: 81
Study 11437863 — intervention group
Group type: COMPARATOR
Intervention: Conventional footwear
Number of subjects: 81
Study 9149578 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 100 micrograms twice daily
Number of subjects: 10
Study 9149578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7956717 — intervention group
Group type: EXPERIMENTAL
Intervention: etofibrate
Number of subjects: 50
Study 7956717 — intervention group
Group type: COMPARATOR
Intervention: gemfibrozil
Number of subjects: 50
Study 2439000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal anti-tetanus serum (ATS)
Number of subjects: 66
Study 2439000 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular anti-tetanus serum (ATS)
Number of subjects: 66
Study 31282290 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential methylation at 227 CpGs associated with expression of 40 nearby miRNAs (cis-miR-eQTMs) at FDR<0.01
Number of subjects: 3565
Study 31282290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional Mendelian randomization (MR) analysis
Number of subjects: 3565
Study 31282290 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of genetic variants in joint analyses
Number of subjects: 3565
Study 31282290 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step MR analysis
Number of subjects: 3565
Study 31697272 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE in hypnosis (n = 23)
Number of subjects: 50
Study 31697272 — intervention group
Group type: COMPARATOR
Intervention: TEE in sedation (n = 27)
Number of subjects: 50
Study 31697272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during TEE
Number of subjects: 50
Study 27166320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders
Number of subjects: 4605
Study 27166320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders (STEMI subgroup)
Number of subjects: 4605
Study 27166320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders (all patients)
Number of subjects: 4605
Study 25937633 — intervention group
Group type: EXPERIMENTAL
Intervention: TM208 (50 and 150 mg·kg ‐1 ·d ‐1) for 18 days
Number of subjects: 0
Study 25937633 — intervention group
Group type: EXPERIMENTAL
Intervention: TM208 (10, 15 and 20 μmol/L) in vitro
Number of subjects: 0
Study 25937633 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (positive control)
Number of subjects: 0
Study 25937633 — intervention group
Group type: COMPARATOR
Intervention: Co-treatment with triclosan (inhibitor of sulfonation)
Number of subjects: 0
Study 24006895 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple letters to parents
Number of subjects: 11088
Study 24006895 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive to school
Number of subjects: 11088
Study 24006895 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive to school administrator plus direct mailing to parents
Number of subjects: 11088
Study 24006895 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting the research by providing additional information to parents and children
Number of subjects: 11088
Study 24006895 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (usual practice: single letter home to parents)
Number of subjects: 11088
Study 21035276 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1726
Study 18991970 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Through Play programme
Number of subjects: 309
Study 18991970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 309
Study 16500776 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (cognitive behaviour therapy Internet program)
Number of subjects: 78
Study 16500776 — intervention group
Group type: COMPARATOR
Intervention: Standard personal development activities (control group)
Number of subjects: 78
Study 15611398 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of botulinum toxin type A into the thyroarytenoid muscle(s)
Number of subjects: 42
Study 15611398 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 42
Study 11014954 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral dose of 150 mg fluconazole for 6 months
Number of subjects: 40
Study 11014954 — intervention group
Group type: COMPARATOR
Intervention: Low oxalate diet with calcium citrate (placebo)
Number of subjects: 40
Study 9293648 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline at 7 ml/kg
Number of subjects: 60
Study 9293648 — intervention group
Group type: COMPARATOR
Intervention: Isotonic lactated Ringer's solution at 7 mg/kg
Number of subjects: 60
Study 8299637 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 100 mg infused over 3 h
Number of subjects: 80
Study 8299637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3571088 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of 600 ml of NaCl-glucose-phosphate solution with approximately 50% hematocrit (n = 6)
Number of subjects: 9
Study 3571088 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (n = 3)
Number of subjects: 9
Study 2827941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy (second and third trimesters)
Number of subjects: 0
Study 2827941 — intervention group
Group type: EXPERIMENTAL
Intervention: Post partum
Number of subjects: 0
Study 2827941 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake (greater than 250 mmol/day)
Number of subjects: 0
Study 2827941 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (less than 50 mmol/day)
Number of subjects: 0
Study 31638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist physiotherapy protocol
Number of subjects: 264
Study 31638942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (referral to a community physiotherapy service)
Number of subjects: 264
Study 29186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 1578
Study 29186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Light labels (MTL)
Number of subjects: 1578
Study 29186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Intake Guides (DIG)
Number of subjects: 1578
Study 29186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations/Warnings (WARN)
Number of subjects: 1578
Study 29186803 — intervention group
Group type: COMPARATOR
Intervention: Nutrition Information Panel (NIP)
Number of subjects: 1578
Study 25406306 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan in Heart Failure with Preserved systolic function trial (I-Preserve)
Number of subjects: 0
Study 25406306 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved trial
Number of subjects: 0
Study 25406306 — intervention group
Group type: COMPARATOR
Intervention: HF-REF in Western Europe
Number of subjects: 0
Study 25406306 — intervention group
Group type: COMPARATOR
Intervention: HF-PEF and HF-REF
Number of subjects: 0
Study 23513399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens and medroxyprogesterone (0.625 mg/d plus medroxyprogesterone 5 mg/d for 10 days)
Number of subjects: 111
Study 23513399 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 111
Study 23513399 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 111
Study 21546627 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM‐102 (fusidic acid) administered in single, multiple, and loading doses
Number of subjects: 0
Study 21546627 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of CEM‐102
Number of subjects: 0
Study 21546627 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM‐102 (fusidic acid)
Number of subjects: 0
Study 21546627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 200
Study 19528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl
Number of subjects: 200
Study 19528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and midazolam
Number of subjects: 200
Study 19528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, midazolam and fentanyl
Number of subjects: 200
Study 16917133 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT) introduced into the arterial line of ECC
Number of subjects: 41
Study 16917133 — intervention group
Group type: COMPARATOR
Intervention: Placebo-DBT
Number of subjects: 41
Study 15523294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nesiritide (0.015 microg/kg/min)
Number of subjects: 185
Study 15523294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nesiritide (0.03 microg/kg/min)
Number of subjects: 185
Study 15523294 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (>= 5 microg/kg/min)
Number of subjects: 185
Study 11744418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 13
Study 11744418 — intervention group
Group type: COMPARATOR
Intervention: Total lymphoid irradiation
Number of subjects: 13
Study 9423913 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted lidocaine 4%
Number of subjects: 34
Study 9423913 — intervention group
Group type: COMPARATOR
Intervention: standard lidocaine 4%
Number of subjects: 34
Study 7506144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg/day
Number of subjects: 200
Study 7506144 — intervention group
Group type: COMPARATOR
Intervention: Seaprose S 60 mg/day
Number of subjects: 200
Study 3101609 — intervention group
Group type: EXPERIMENTAL
Intervention: LNT injection following surgical therapy (Ax + Ox)
Number of subjects: 33
Study 3101609 — intervention group
Group type: EXPERIMENTAL
Intervention: LNT injection
Number of subjects: 33
Study 3101609 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 33
Study 3101609 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 33
Study 29128558 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 20
Study 29128558 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 20
Study 26673586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nebulised heparin (50,000 U)
Number of subjects: 40
Study 26673586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25155048 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 95
Study 25155048 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 95
Study 25155048 — intervention group
Group type: COMPARATOR
Intervention: Both CAS and standard instrumentation
Number of subjects: 95
Study 25155048 — intervention group
Group type: COMPARATOR
Intervention: Entire patient population
Number of subjects: 95
Study 22184381 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus vandetanib (100 mg)
Number of subjects: 142
Study 22184381 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 142
Study 22184381 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent vandetanib (after crossover)
Number of subjects: 142
Study 19949861 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy with submucosal injection of triamcinolone (40 mg)
Number of subjects: 50
Study 19949861 — intervention group
Group type: COMPARATOR
Intervention: Internal urethrotomy without triamcinolone (control group)
Number of subjects: 50
Study 17967221 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR) treatment for 3 years
Number of subjects: 465
Study 16002025 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (100, 100, 130 mg/MWF) with contingency management (CM)
Number of subjects: 140
Study 16002025 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (100, 100, 130 mg/MWF) without CM
Number of subjects: 140
Study 16002025 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (30, 30, 39 mg/MWF) with CM
Number of subjects: 140
Study 16002025 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (30, 30, 39 mg/MWF) without CM
Number of subjects: 140
Study 16002025 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (100, 100, 130 mg/MWF) with CM
Number of subjects: 140
Study 11833838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (HC/IB)
Number of subjects: 147
Study 11833838 — intervention group
Group type: COMPARATOR
Intervention: Combination oxycodone 5 mg and acetaminophen 325 mg (OX/AC)
Number of subjects: 147
Study 10189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention focusing on a healthy diet and exercise
Number of subjects: 3000
Study 10189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined with standard diet and exercise recommendations
Number of subjects: 3000
Study 10189543 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with standard diet and exercise recommendations
Number of subjects: 3000
Study 10189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone combined with standard diet and exercise recommendations
Number of subjects: 3000
Study 10189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet and exercise recommendations
Number of subjects: 3000
Study 7559264 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg
Number of subjects: 0
Study 7559264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 50 micrograms i.v. dose
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 250 micrograms oral treatment
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 500 micrograms oral treatment
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 750 micrograms oral treatment
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride (all doses)
Number of subjects: 0
Study 2373136 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride
Number of subjects: 0
Study 7295072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anticholinergics, sulphoglicopeptide and sucralfate
Number of subjects: 112
Study 7295072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic plus sucralfate
Number of subjects: 112
Study 7295072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 29460712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic alpha stimulation (RAS)
Number of subjects: 22
Study 29460712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic delta stimulation (RDS)
Number of subjects: 22
Study 29506563 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention delivered in 10 wards
Number of subjects: 1450
Study 29506563 — intervention group
Group type: COMPARATOR
Intervention: Normal practice in 10 comparator wards
Number of subjects: 1450
Study 27555188 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® classic (GSc)
Number of subjects: 104
Study 27555188 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® direct (GSd)
Number of subjects: 104
Study 27555188 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 104
Study 27555188 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 104
Study 24913546 — intervention group
Group type: EXPERIMENTAL
Intervention: Less encompassing instructions
Number of subjects: 0
Study 24913546 — intervention group
Group type: COMPARATOR
Intervention: More encompassing instructions
Number of subjects: 0
Study 22380600 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity back endurance (HIBE) training
Number of subjects: 26
Study 22380600 — intervention group
Group type: COMPARATOR
Intervention: Low intensity abdominal (LOAB) training (control)
Number of subjects: 26
Study 19708170 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis
Number of subjects: 979
Study 19708170 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups identified as 'at risk' based on factors
Number of subjects: 979
Study 17961876 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib 2.5
Number of subjects: 0
Study 17961876 — intervention group
Group type: COMPARATOR
Intervention: Tritanrix-Hep B and Hiberix
Number of subjects: 0
Study 15203788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine withdrawal symptoms
Number of subjects: 191
Study 15203788 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal index
Number of subjects: 191
Study 11284567 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction and internal fixation
Number of subjects: 280
Study 11284567 — intervention group
Group type: COMPARATOR
Intervention: Cemented Thompson hemiarthroplasty
Number of subjects: 280
Study 11284567 — intervention group
Group type: COMPARATOR
Intervention: Cemented Monk bipolar hemiarthroplasty
Number of subjects: 280
Study 11284567 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty
Number of subjects: 280
Study 11284567 — intervention group
Group type: COMPARATOR
Intervention: Bipolar prosthesis
Number of subjects: 280
Study 9842807 — intervention group
Group type: EXPERIMENTAL
Intervention: Information + modeling + coping-based program (OR tour + videotape + child-life preparation)
Number of subjects: 75
Study 9842807 — intervention group
Group type: COMPARATOR
Intervention: Information + modeling-based program (OR tour + videotape)
Number of subjects: 75
Study 9842807 — intervention group
Group type: COMPARATOR
Intervention: Information-based program (OR tour)
Number of subjects: 75
Study 9842807 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive program (Information + modeling + coping-based)
Number of subjects: 75
Study 9842807 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Information + modeling-based and Information-based programs)
Number of subjects: 75
Study 7510746 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR V beta 5.2(39-59) and V beta 6.1(39-59) peptides at low doses (100 to 300 micrograms)
Number of subjects: 11
Study 7510746 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR V beta 5.2(39-59) and V beta 6.1(39-59) peptides
Number of subjects: 11
Study 2777565 — intervention group
Group type: EXPERIMENTAL
Intervention: One Step Skin Prep
Number of subjects: 60
Study 2777565 — intervention group
Group type: COMPARATOR
Intervention: ECG Prep Pads
Number of subjects: 60
Study 2777565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 1101065 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (high concentration of antibodies to surface components of hepatitis B virus, 442 mug per milliliter)
Number of subjects: 58